Dysphagia is the symptom of difficulty in swallowing. It is reported that dysphagia occurs in 29% to 64% of a stroke patient and in up to 81% of a Parkinson's disease patient. Further, even in the case of a disease which does not directly cause dysphagia, dysphagia may still occur, where the patient does not properly swallow foods due to the patient's overall perception and body states or external effects such as airway intubation or a tracheotomy. In this case, even with differences in the severity and cause of each disease, dysphagia may become a cause of aspiration, pneumonia, dehydration or malnutrition and may lead to death after all.
This device which monitors and treats for dysphagia comprises of 3 components. Dysphagia measuring sensor units attached to the neck of a patient sense for dysphagia signals, electrical stimulation electrode units attached to the patient's neck then provide electrical stimulation to the neck of the patient to resolve the dysphagia while a control unit controls the dysphagia measuring sensor units and electrical stimulation electrode units.
The global dysphagia management revenues are likely to reach US$ 4,101.3 million value by the end of 2024, a majority of which will be accounted by nutritional solutions products. Global sales of thickeners in nutritional solutions (as dysphagia management products) will net revenues worth over US$ 1,700 million during the forecast period.
According to the report, over the forecast period, the global dysphagia management market will expand at a healthy CAGR of 6.2%. Growth in global demand for dysphagia management will be paralleled with improvement of medical services & facilities in the global healthcare sector. Increasing presence of specialty clinics and retail pharmacies will further add to the distribution of dysphagia management drugs and treatment solutions.
In terms of global revenues, however, hospital pharmacies will continue to lead the worldwide dysphagia management market by reaping more than US$ 1.5 billion by 2024. Although, growth of the global dysphagia management market is likely to be restrained by side-effects of products sold as dysphagia drugs & tubes. Additionally, losing out on market exclusivity is also a key challenge incurred during sales of dysphagia drugs as OTC medications.
1. The present device can measure and treat for dysphagia by using an electrical stimulation electrode unit which applies electrical stimulation to the neck of a patient according to the dysphagia signal measured by the dysphagia measurement sensor unit.
2. The advantage of this device is that dysphagia can be measured by a simple and non-invasive method without the use of complicated dysphagia measurement apparatus such as those used for video fluoroscopic swallowing studies or fiberoptic endoscopic evaluation studies.
3. A display analysis unit which analyzes and displays the dysphagia signal is provided, allowing for the simultaneous monitoring of the patient's reaction and treatment of dysphagia. With the possibility of evaluating whether the patient reacts appropriately, the device performs a feedback role of allowing the patient to see his own reaction.